• Phone: +1-631-791-1145
  • Email: sales@imarcgroup.com

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

The global orphan drugs market exhibited moderate growth during 2014-2019. Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further. Looking forward, IMARC Group expects the global orphan drugs market to exhibit moderate growth during the next five years.

Breakup by Drug Type:

  • Biological
  • Non-Biological
     

Breakup by Disease Type:

  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others
     

Breakup by Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV
     

Breakup by Top Selling Drugs:

  • Revlimid
  • Rituxan
  • Copaxone
  • Opdivo
  • Keytruda
  • Imbruvica
  • Avonex
  • Sensipar
  • Soliris
  • Others
     

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa


Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global orphan drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global orphan drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the disease type?
  • What is the breakup of the market based on the phase?
  • What is the breakup of the market based on the top selling drugs?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global orphan drugs market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology 

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Orphan Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Drug Type
    6.1    Biological
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Non-Biological
        6.2.1 Market Trends
        6.2.2 Market Forecast
7    Market Breakup by Disease Type
    7.1    Oncology
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Hematology
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Neurology
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Cardiovascular
        7.4.1 Market Trends
        7.4.2 Market Forecast
    7.5    Others
        7.5.1 Market Trends
        7.5.2 Market Forecast
8    Market Breakup by Phase
    8.1    Phase I
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Phase II
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Phase III
        8.3.1 Market Trends
        8.3.2 Market Forecast
    8.4    Phase IV
        8.4.1 Market Trends
        8.4.2 Market Forecast
9    Market Breakup by Top Selling Drugs
    9.1    Revlimid
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Rituxan
        9.2.1 Market Trends
        9.2.2 Market Forecast
    9.3    Copaxone
        9.3.1 Market Trends
        9.3.2 Market Forecast
    9.4    Opdivo
        9.4.1 Market Trends
        9.4.2 Market Forecast
    9.5    Keytruda
        9.5.1 Market Trends
        9.5.2 Market Forecast
    9.6    Imbruvica
        9.6.1 Market Trends
        9.6.2 Market Forecast
    9.7    Avonex
        9.7.1 Market Trends
        9.7.2 Market Forecast
    9.8    Sensipar
        9.8.1 Market Trends
        9.8.2 Market Forecast
    9.9    Soliris
        9.9.1 Market Trends
        9.9.2 Market Forecast
    9.10    Others
        9.10.1 Market Trends
        9.10.2 Market Forecast
10    Market Breakup by Distribution Channel
    10.1    Hospital Pharmacy
        10.1.1 Market Trends
        10.1.2 Market Forecast
    10.2    Retail Pharmacy
        10.2.1 Market Trends
        10.2.2 Market Forecast
    10.3    Online Stores
        10.3.1 Market Trends
        10.3.2 Market Forecast
    10.4    Others
        10.4.1 Market Trends
        10.4.2 Market Forecast
11    Market Breakup by Region
    11.1    North America
        11.1.1 United States
           11.1.1.1 Market Trends
           11.1.1.2 Market Forecast
        11.1.2 Canada
           11.1.2.1 Market Trends
           11.1.2.2 Market Forecast
    11.2    Asia Pacific
        11.2.1 China
           11.2.1.1 Market Trends
           11.2.1.2 Market Forecast
        11.2.2 Japan
           11.2.2.1 Market Trends
           11.2.2.2 Market Forecast
        11.2.3 India
           11.2.3.1 Market Trends
           11.2.3.2 Market Forecast
        11.2.4 South Korea
           11.2.4.1 Market Trends
           11.2.4.2 Market Forecast
        11.2.5 Australia
           11.2.5.1 Market Trends
           11.2.5.2 Market Forecast
        11.2.6 Indonesia
           11.2.6.1 Market Trends
           11.2.6.2 Market Forecast
        11.2.7 Others
           11.2.7.1 Market Trends
           11.2.7.2 Market Forecast
    11.3    Europe
        11.3.1 Germany
           11.3.1.1 Market Trends
           11.3.1.2 Market Forecast
        11.3.2 France
           11.3.2.1 Market Trends
           11.3.2.2 Market Forecast
        11.3.3 United Kingdom
           11.3.3.1 Market Trends
           11.3.3.2 Market Forecast
        11.3.4 Italy
           11.3.4.1 Market Trends
           11.3.4.2 Market Forecast
        11.3.5 Spain
           11.3.5.1 Market Trends
           11.3.5.2 Market Forecast
        11.3.6 Russia
           11.3.6.1 Market Trends
           11.3.6.2 Market Forecast
        11.3.7 Others
           11.3.7.1 Market Trends
           11.3.7.2 Market Forecast
    11.4    Latin America
        11.4.1 Brazil
           11.4.1.1 Market Trends
           11.4.1.2 Market Forecast
        11.4.2 Mexico
           11.4.2.1 Market Trends
           11.4.2.2 Market Forecast
        11.4.3 Others
           11.4.3.1 Market Trends
           11.4.3.2 Market Forecast
    11.5    Middle East and Africa
        11.5.1 Market Trends
        11.5.2 Market Breakup by Country
        11.5.3 Market Forecast
12    SWOT Analysis
    12.1    Overview
    12.2    Strengths
    12.3    Weaknesses
    12.4    Opportunities
    12.5    Threats
13    Value Chain Analysis
14    Porters Five Forces Analysis

    14.1    Overview
    14.2    Bargaining Power of Buyers
    14.3    Bargaining Power of Suppliers
    14.4    Degree of Competition
    14.5    Threat of New Entrants
    14.6    Threat of Substitutes
15    Price Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Key Players
    16.3    Profiles of Key Players
        16.3.1    AbbVie Inc.
           16.3.1.1 Company Overview
           16.3.1.2 Product Portfolio 
           16.3.1.3 Financials
           16.3.1.4 SWOT Analysis
        16.3.2    Alexion Pharmaceuticals Inc.
           16.3.2.1 Company Overview
           16.3.2.2 Product Portfolio 
           16.3.2.3 Financials
           16.3.2.4 SWOT Analysis
        16.3.3    Amgen Inc.
           16.3.2.1 Company Overview
           16.3.2.2 Product Portfolio 
           16.3.2.3 Financials
           16.3.2.4 SWOT Analysis
        16.3.4    Biogen Inc.
           16.3.4.1 Company Overview
           16.3.4.2 Product Portfolio 
           16.3.4.3 Financials
           16.3.4.4 SWOT Analysis
        16.3.5    Bristol Myers Squibb Company
           16.3.5.1 Company Overview
           16.3.5.2 Product Portfolio 
           16.3.5.3 Financials
           16.3.5.4 SWOT Analysis
        16.3.6    F. Hoffmann-La Roche AG (Roche Holding AG)
           16.3.6.1 Company Overview
           16.3.6.2 Product Portfolio 
           16.3.6.3 SWOT Analysis
        16.3.7    Jazz Pharmaceuticals Plc
           16.3.7.1 Company Overview
           16.3.7.2 Product Portfolio 
           16.3.7.3 Financials
           16.3.7.4 SWOT Analysis
        16.3.8    Johnson & Johnson 
           16.3.8.1 Company Overview
           16.3.8.2 Product Portfolio
           16.3.8.3 Financials
           16.3.8.4 SWOT Analysis
        16.3.9    Merck & Co. Inc.
           16.3.9.1 Company Overview
           16.3.9.2 Product Portfolio 
           16.3.9.3 Financials
           16.3.9.4 SWOT Analysis
        16.3.10    Novartis AG
           16.3.10.1 Company Overview
           16.3.10.2 Product Portfolio 
           16.3.10.3 Financials
           16.3.10.4 SWOT Analysis
        16.3.11    Pfizer Inc.
           16.3.11.1 Company Overview
           16.3.11.2 Product Portfolio 
           16.3.11.3 Financials
           16.3.11.4 SWOT Analysis
        16.3.12    Sanofi S.A. 
           16.3.12.1 Company Overview
           16.3.12.2 Product Portfolio 
           16.3.12.3 Financials
           16.3.12.4 SWOT Analysis
        16.3.13    Takeda Pharmaceutical Company Limited 
           16.3.13.1 Company Overview
           16.3.13.2 Product Portfolio 
           16.3.13.3 Financials
           16.3.13.4 SWOT Analysis
        16.3.14    Teva Pharmaceutical Industries Ltd
           16.3.14.1 Company Overview
           16.3.14.2 Product Portfolio 
           16.3.14.3 Financials
           16.3.14.4 SWOT Analysis

List of Figures

Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US$), 2014-2019
Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2019
Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2019
Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2019
Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2019
Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2019
Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2019
Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US$), 2020-2025
Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US$), 2014 & 2019
Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US$), 2014 & 2019
Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US$), 2014 & 2019
Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US$), 2014 & 2019
Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US$), 2014 & 2019
Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US$), 2014 & 2019
Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2014 & 2019
Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US$), 2014 & 2019
Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US$), 2014 & 2019
Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US$), 2014 & 2019
Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US$), 2014 & 2019
Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US$), 2014 & 2019
Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US$), 2014 & 2019
Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US$), 2014 & 2019
Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US$), 2015 & 2019
Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US$), 2015 & 2019
Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US$), 2014 & 2019
Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US$), 2014 & 2019
Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US$), 2014 & 2019
Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US$), 2014 & 2019
Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US$), 2014 & 2019
Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2014 & 2019
Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US$), 2014 & 2019
Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2014 & 2019
Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 68: China: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 72: India: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 86: France: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US$), 2014 & 2019
Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
Figure 110: Global: Orphan Drugs Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2019 and 2025
Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2020-2025
Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2020-2025
Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US$), 2020-2025
Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US$), 2020-2025
Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2020-2025
Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US$), 2020-2025
Table 8: Global: Orphan Drugs Market Structure
Table 9: Global: Orphan Drugs Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com

Social Links